128 related articles for article (PubMed ID: 38752557)
21. Recent Alcohol Use Is Associated With Increased Pre-exposure Prophylaxis (PrEP) Continuation and Adherence Among Pregnant and Postpartum Women in South Africa.
Miller AP; Shoptaw S; Moucheraud C; Mvududu R; Essack Z; Gorbach PM; Myer L; Davey DLJ
J Acquir Immune Defic Syndr; 2023 Mar; 92(3):204-211. PubMed ID: 36413977
[TBL] [Abstract][Full Text] [Related]
22. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
[TBL] [Abstract][Full Text] [Related]
23. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
24. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
25. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
26. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
Celum CL; Bukusi EA; Bekker LG; Delany-Moretlwe S; Kidoguchi L; Omollo V; Rousseau E; Travill D; Morton JF; Mogaka F; O'Malley G; Barnabee G; van der Straten A; Donnell D; Parikh UM; Kudrick L; Anderson PL; Haberer JE; Wu L; Heffron R; Johnson R; Morrison S; Baeten JM;
J Int AIDS Soc; 2022 Jul; 25(7):e25962. PubMed ID: 35822945
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
[TBL] [Abstract][Full Text] [Related]
28. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project.
Cohen SE; Vittinghoff E; Bacon O; Doblecki-Lewis S; Postle BS; Feaster DJ; Matheson T; Trainor N; Blue RW; Estrada Y; Coleman ME; Elion R; Castro JG; Chege W; Philip SS; Buchbinder S; Kolber MA; Liu AY
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):439-48. PubMed ID: 25501614
[TBL] [Abstract][Full Text] [Related]
29. Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women.
Hurwitz KE; Isehunwa OO; Hendrickson KR; Jaggernath M; Kriel Y; Smith PM; Mathenjwa M; Bennett K; Psaros C; Baeten JM; Bangsberg DR; Haberer JE; Smit JA; Matthews LT
Front Reprod Health; 2023; 5():1263422. PubMed ID: 37860779
[TBL] [Abstract][Full Text] [Related]
30. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
31. Integration of pre-exposure prophylaxis services into public HIV care clinics in Kenya: a pragmatic stepped-wedge randomised trial.
Irungu EM; Mugwanya KK; Mugo NR; Bukusi EA; Donnell D; Odoyo J; Wamoni E; Peacock S; Morton JF; Ngure K; Mugambi M; Mukui I; O'Malley G; Baeten JM;
Lancet Glob Health; 2021 Dec; 9(12):e1730-e1739. PubMed ID: 34798031
[TBL] [Abstract][Full Text] [Related]
32. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
[TBL] [Abstract][Full Text] [Related]
33. Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.
Roberts ST; Haberer J; Celum C; Mugo N; Ware NC; Cohen CR; Tappero JW; Kiarie J; Ronald A; Mujugira A; Tumwesigye E; Were E; Irungu E; Baeten JM;
J Acquir Immune Defic Syndr; 2016 Nov; 73(3):313-322. PubMed ID: 27243900
[TBL] [Abstract][Full Text] [Related]
34. Stepped care to optimize pre-exposure prophylaxis (PrEP) effectiveness in pregnant and postpartum women (SCOPE-PP) in South Africa: a randomized control trial.
Joseph Davey DL; Dovel K; Cleary S; Khadka N; Mashele N; Silliman M; Mvududu R; Nyemba DC; Coates TJ; Myer L
BMC Public Health; 2022 Jul; 22(1):1306. PubMed ID: 35799121
[TBL] [Abstract][Full Text] [Related]
35. The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV.
Anderson KM; Blumenthal J; Jain S; Sun X; Amico KR; Landovitz R; Zachek CM; Morris S; Moore DJ; Stockman JK
BMC Public Health; 2024 May; 24(1):1461. PubMed ID: 38822300
[TBL] [Abstract][Full Text] [Related]
36. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
37. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
[TBL] [Abstract][Full Text] [Related]
38. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
[TBL] [Abstract][Full Text] [Related]
39. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
40. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
